Transplant Diagnostics Market is Projected to Reach Valuation Of US$ 1,127.6 Million By 2025

The Global Transplant Diagnostics Market, By Product Type (Instrument, Reagents & Kits, and Software), By Technology (Molecular Assay (PCR-Based and Sequencing – Based), and Non-Molecular Assay), By Application (Tissue Typing, Infectious Disease Testing, Serum-Cross Matching, and Blood Profiling), By Organ Type (Kidney, Liver, Heart, Lungs, Pancreas, and Others), By End User (Hospitals & Transplant Centers, Research Laboratories & Academic Institutes, and Commercial Service Providers), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 544.2 million in 2016 and is projected to exhibit a CAGR of 8.4% over the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Growth of the transplant diagnostics market is attributed to rising prevalence of chronic diseases leading to multiple organ failures, possible prediction of organ rejection episodes with the help of transplant diagnostics, initiatives by government organizations to promote organ donation, and increasing research and development by leading players to enhance technologies in transplant diagnostics.

Request Sample Copy of Research @ https://www.coherentmarketinsights.com/insight/request-sample/1335

Manufacturers are focusing on introducing innovative transplant diagnostic solutions in line with needs and demands of customers. For instance, Thermo Fisher Scientific launched NXType NGS HLA typing assay in 2015 consisting of SSP, SSO, and SBT molecular typing technologies. Also, Immucor, Inc. launched MIA FORA NGS Flex HLA Typing Assay in 2017, which provides coverage of up to 11 HLA genes. Furthermore, Immucor, Inc. launched kSORT—a molecular gene expression assay—in 2016 for kidney transplant patients. Moreover, Qiagen launched GeneReader NGS system in 2015 that provides NGS solution and helps laboratories in obtaining accurate results. CareDx, Inc. launched Olerup QTYPE in 2016, which is an easy-to-use alternative for rapid HLA typing. Furthermore, GenDx signed a global reseller agreement with Thermo Fisher Scientific in 2017, under which former gained rights to offer latter’s Ion Torrent next-generation sequencing systems.

Browse 48 Market Data Tables and 37 Figures spread through 187 Pages and in-depth TOC on Transplant Diagnostics Market by Product Type (Instrument, Reagents & Kits, and Software), by Technology (Molecular Assay (PCR-Based, Sequencing – Based), and Non-Molecular Assay), by Application (Tissue Typing, Infectious Disease ,.Testing, Serum-Cross Matching, and Blood Profiling), by Organ Type (Kidney, Liver, Heart, Lungs, Pancreas, and Others), by End User (Hospitals & Transplant Centers, Research Laboratories & Academic Institutes, and Commercial Service Providers) and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) - Global Forecast to 2025

Manufacturers are increasingly focusing on research and development of transplant diagnostic products through mergers and acquisition activities. For instance, Thermo Fisher Scientific acquired Linkage Bio in 2017, which became a part of formers transplant diagnostics business, One Lambda. Xenotransplantation (from different species) could aid in reducing the gap in supply and demand of transplant organs. Research on innovative transplant options such as pig-to-human transplants and stem cell transplants is being conducted by various manufacturers. TAI Diagnostics, Inc., which provides a highly sensitive and non-invasive diagnostic test to monitor transplanted organs, entered into a partnership with United Therapeutics and raised significant capital in January 2018 for R&D. Moreover, Transplant Genomics, Inc. entered into a collaboration with Mayo Clinic Center, to develop diagnostic tests for organ transplant patients; in an immunosuppressive clinical trials collaboration with Astellas Pharmaceuticals; and with Quark Pharmaceuticals, in discovery and development collaboration in the year 2016. Natera, Inc. and University of California, San Francisco (UCSF), entered into a research collaboration in 2016, to study DNA markers of Kidney Transplant Rejection.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1335

Key Takeaways of the Transplant Diagnostics Market:

The global transplant diagnostics market is expected to exhibit a CAGR of 4% over the forecast period (2017–2025), owing to increasing product offerings by key players such as Thermo Fisher Scientific, and Qiagen in transplant diagnostics

Increasing competition in the market has led to increasing focus of key players on continuous product development, in order to enhance their market share. This is expected to aid in market growth over the forecast period.

Increasing effectiveness of transplant diagnostics tests such as identification of more robust biomarkers in providing viable results in organ transplant is expected to boost growth of the transplant diagnostics market over the forecast period

Major players operating in the global transplant diagnostics market are Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., F. Hoffman-La Roche Ltd., Immucor, Inc., Becton Dickinson and Company, bioMérieux S.A., Illumina, Inc., CareDx, Inc., and GenDx.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,
#3200
Seattle, WA 98154

This release was published on openPR.